Risk-Proportionate Approaches to Study Design

Part of Good Clinical Practice (GCP) — ICH E6(R3): Clinical Trial Protocol and Design.

About 6 minutes. Free, in your language, no account needed.

Why this matters

Treating every trial the same way wastes effort and hides real risk. A protocol that collects data nobody will analyze still costs participant time, staff time and money. The International Council for Harmonisation (ICH) guideline ICH E6(R3) states in its Introduction that it "encourages a risk-based and proportionate approach to the conduct of a clinical trial." That sentence changes how protocols should be written.

What proportionate means in E6(R3)

Principle 7 is the anchor. It reads:

"Clinical trial processes, measures and approaches should be implemented in a way that is proportionate to the risks to participants and to the importance of the data collected and that avoids unnecessary burden on participants and investigators."

Principle 7 has four sub-points, and each one does separate work.

• 7.1 — two kinds of risk. Trial processes should be proportionate to the risks inherent in the trial and the importance of the information collected. Risks here include risks to the rights, safety and well-being of participants, and risks to the reliability of the trial results. Both count.
• 7.2 — risks beyond usual medical care. The focus should be on the risks associated with trial participation. For clinical trials involving patients, the focus should be on risks that go beyond those associated with usual medical care. Principle 7.2 adds that an investigational product with a marketing authorization may carry different risks in the trial context than in usual care, and this should be taken into consideration.
• 7.3 — risk is not fixed. Risks to critical to quality factors should be managed proactively and adjusted when new or unanticipated issues arise once the trial has begun.
• 7.4 — no unnecessary burden. Trial processes should be operationally feasible and avoid unnecessary complexity, procedures and data collection. Trial processes should support the key trial objectives. The sponsor should not place unnecessary burden on participants and investigators.

Sub-point 7.2 is the one most often misread. It does not say that usual-care risks are ignored. It says the trial-specific controls should concentrate on what the trial adds. A blood sample the patient would have given anyway does not need the same protocol machinery as a biopsy the trial introduced.

How proportionality shows up in the protocol

Principle 8 turns proportionality into a document requirement. Trials should be described in a clear, concise, scientifically sound and operationally feasible protocol. Principle 8.3 applies the same standard to the statistical analysis plan, the data management plan and the monitoring plan.

Section 3.1.4 repeats the duty for the sponsor. Ensure all aspects of the trial are operationally feasible. Avoid unnecessary complexity, procedures and data collection. Keep protocols, data acquisition tools and other operational documents fit for purpose, clear, concise and consistent.

Appendix B adds a design technique. Building adaptability into the protocol, for example by including acceptable ranges for specific protocol provisions, can reduce the number of deviations and sometimes the need for an amendment. That adaptability must not harm participant safety or the scientific validity of the trial. A visit window of plus or minus three days is proportionality written into the protocol.

Appendix B.12.1 asks the protocol to describe the identified critical to quality factors, the associated risks and the risk mitigation strategies, unless documented elsewhere. Principle 6.2 defines critical to quality factors as attributes of a trial that are fundamental to the protection of participants and to the reliability and interpretability of the trial results, and requires them to be identified prospectively.

Proportionality also runs the other way. A first-in-human trial of a novel mechanism justifies intensive monitoring, close safety review and tight windows. Proportionate does not mean light. It means matched.

A short test before adding anything to a protocol

Ask four questions about every procedure, assessment and data field.

• Purpose — which objective or endpoint does this support?
• Beyond usual care — does this add risk or burden the patient would not otherwise carry?
• Use — will anyone analyze this, and what decision changes if the result differs?
• Deliverability — can an ordinary site perform this reliably, in every region where the trial will run?

If a data field survives none of those questions, remove it. Removing it is a quality action, not a shortcut.

Annex 2, in one paragraph

ICH E6(R3) Annex 2 provides additional GCP considerations for trials that incorporate decentralized elements, pragmatic elements and real-world data. It was adopted at Step 4 on 3 June 2026, with a legal effective date in the European Union of 15 January 2027. Annex 2 states that it should not be read as an endorsement of any specific methodology, and should be read together with the Principles and Annex 1. This course is scoped to the Principles and Annex 1. Treat Annex 2 as context for where the guideline is going, and consult it directly when your trial uses those elements.

In practice

Priya coordinates a trial of an already authorized diabetes medicine used in a new comparison. Most visits happen in the routine diabetes clinic. The draft protocol adds a monthly laboratory panel of 22 analytes and a 40-item quality of life questionnaire at every visit.

Tomas, the monitor, raises two questions at the design review. Only four analytes feed a defined endpoint or a safety rule. The questionnaire is a secondary endpoint measured at three time points in the statistical analysis plan, but the protocol collects it twelve times.

The sponsor reduces the panel to the four analytes plus the usual-care tests the clinic already performs. The questionnaire is collected at the three analysis time points only. Participant time per visit falls by roughly 30 minutes.

Nothing scientific was lost. What was removed was burden. Priya's site now has time to review the safety laboratory results the same day.

One warning. Proportionality is a judgment the sponsor documents, not a permission for a site to skip protocol steps. If a required assessment feels unnecessary, raise it with the sponsor and ask for an amendment. Do not solve it at the bedside.

Key takeaways

• Principle 7 requires trial processes to be proportionate to the risks to participants and to the importance of the data collected, and to avoid unnecessary burden on participants and investigators.
• Principle 7.1 counts two kinds of risk: risk to participants' rights, safety and well-being, and risk to the reliability of the trial results.
• Principle 7.2 directs the focus, for trials involving patients, to the risks that go beyond those associated with usual medical care.
• Principle 7.3 requires risks to critical to quality factors to be managed proactively and adjusted when new issues arise after the trial begins.
• Section 3.1.4 and Principle 7.4 both require the sponsor to avoid unnecessary complexity, procedures and data collection.
• Proportionate means matched to risk, so a high-risk trial justifies more intensive controls, not fewer.